|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The blind men 'see' the elephant-the many faces of fatty liver disease显示文摘Nonalcoholic fatty liver disease (NAFLD) is a group of diseases with excess fat in liver in the absence of a poorly defined limit of alcohol consumption. Most common variety, a universal public health problem, is associated with insulin resistance caused by a host of genetic and epigenetic defects modulated by life style and environmental factors. In fact the term NAFLD is loose to incorporate so many etiologies except alcoholism and few other etiologies, presenting as fat in liver. However as a sign fatty liver is very important in predicting the risk of diabetes, cardiovascular disease, stroke, cirrhosis and cancer. Abnormal fat accumulation can result from several defects in nuclear receptors associated with lipid sensing, synthesis and oxidation like LXR, FXR, SREBP, ChREBP and PPAR; defects in the lipid influx-efflux channels, insulin signaling, proteins involved in fatty acid catabolism, defects in adipose tissue development and function, inappropriate nutrition and finally defects in neural regulatory mechanisms. The progress of the disease is determined by the basic defects which results in fat accumulation, an individual’s immunological response to the accumulated fat and its derivatives and the oxidant stress response. Congregation of unrelated genetic defects under same diagnosis ‘NAFLD’ can result in inefficient patient management. Further studies are required to understand the molecular basis of fatty liver to enable a personalized management of diseases presenting as fatty liver in the absence of alcohol abuse. | Madhusudana Girija Sanal | 2008 | World Journal of Gastroenterology2008，14，6： | 10 |
| 2 | Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?显示文摘Fatty liver is present in over ten percentage of the world population and it is a growing public health problem.Nonalcoholic fatty liver disease(NAFLD) is not a single disease,but encompasses a spectrum of diseases of different etiologies.It is difficult to find highly specific and sensitive diagnostic biomarkers when a disease is very complex.Therefore,we should aim to find relevant prognostic markers rather than accurate diagnostic markers which will help to minimize the frequency of liver biopsies to evaluate disease progression.There are several biomarker panels commercially available,however,there is no clear evidence that more sophisticated panels are better compared to simple criteria such as,presence of diabetes over five years,metabolic syndrome,obesity,obstructive sleep apnea,aspartate transaminase/alanine transaminase(ALT) ratio > 0.8 or ferritin levels > 1.5 times normal in patients with over six month history of raised ALT and/or ultrasonological evidence of fat in the liver.Currently the biomarker panels are not a replacement for a liver biopsy.However the need and benefit of liver biopsy in NAFLD is questionable because there is no convincing evidence that biopsy and detailed staging of NAFLD improves the management of NAFLD and benefits the patient.After all there is no evidence based treatment for NAFLD other than management of lifestyle and components of 'metabolic syndrome'. | Madhusudana Girija Sanal | 2015 | World Journal of Gastroenterology2015，21，11： | 4 |
| 3 | Future of liver transplantation: Non-human primates for patient-specific organs from induced pluripotent stem cells显示文摘Strategies to fill the huge gap in supply versus demand of human organs include bioartificial organs, growing humanized organs in animals, cell therapy, and implantable bioengineered constructs. Reproducing the complex relations between different cell types, generation of adequate vasculature, and immunological complications are road blocks in generation of bioengineered organs, while immunological complications limit the use of humanized organs produced in animals. Recent developments in induced pluripotent stem cell (iPSC) biology offer a possibility of generating human, patient-specific organs in non-human primates (NHP) using patient-derived iPSC and NHP-derived iPSC lacking the critical developmental genes for the organ of interest complementing a NHP tetraploid embryo. The organ derived in this way will have the same human leukocyte antigen (HLA) profile as the patient. This approach can be curative in genetic disorders as this offers the possibility of gene manipulation and correction of the patient's genome at the iPSC stage before tetraploid complementation. The process of generation of patient-specific organs such as the liver in this way has the great advantage of making use of the natural signaling cascades in the natural milieu probably resulting in organs of great quality for transplantation. However, the inexorable scientific developments in this direction involve several social issues and hence we need to educate and prepare society in advance to accept the revolutionary consequences, good, bad and ugly. | Madhusudana Girija Sanal | 2011 | World Journal of Gastroenterology2011，17，32： | 2 |
| 4 | Detemunation of optimum conditions for SC- ( CO2+ethanol ) extraction of β-carotene from apricot pomace using response surface methodology显示文摘 | SANAL I S BAYRAKTAR E MEHMETOGLU U | 2005 | The Journal of Supercritical Fluids2005，34，3： | 1 |
| 5 | Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper- IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency 显示文摘 | Quartier P Bustamante J Sanal O | 2004 | Clin Immunol2004，110，1： | 1 |
| 6 | Cernunnos deficiency: a case report 显示文摘 | Turul T Tezean I Sanal O | 2011 | J lnvestigAllergol Clin hi munol2011，21，4： | 1 |
| 7 | Gemcitabine and vinorelbine combination in patients with metastatic breast cancer 显示文摘 | Sanal S M Gokmen E Karabulut B | 2002 | Breast J2002，8，3： | 1 |
| 8 | Osteochondritis dissecans in a patient with hyperimmunoglobulin E syndrome显示文摘 | Kilic S S Sanal O Tezcan I | 2002 | Turk J Pediatr2002，41，9： | 1 |
| 9 | Clinical immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced cytidine deaminase deficiency显示文摘 | Quartier P Sanal O Bustamante J | 2004 | Clin Immunol2004，110，1： | 1 |
| 10 | cardiac sarcoidosis: a comprehensive review显示文摘 | Sekhri V Sanal S Delorenzo LJ | 2011 | Arch Med Sci2011，7，4： | 1 |
| 11 | Imaging features of benign adrenal cysts显示文摘 | Sanal HT Kocaoglu M Yildirim D | 2006 | Eur J Radiol2006，60，3： | 1 |
| 12 | Imaging features of benign adrenal cysts显示文摘 | Sanal HT Kocaoglu M Yildirim D | 2006 | Eur J Radiol2006，60，3： | 1 |
| 13 | Novel Igα(CD79a)gene mutation in a Turkish patient with B cell deficient agammaglobulinemia 显示文摘 | Wang Y Kanegane H Sanal O | 2002 | Am J Med Genet2002，108，4： | 1 |
| 14 | A pilot study on the usefulness of body mass index and waist hip ratio as a predictive tool for gestational diabetes in Asian Indians 显示文摘 | Madhavan A Beena Kumari R Sanal MG | 2008 | Gynecol Endocrinol2008，24，： | 1 |
| 15 | Growth of ITO Thin Films on Polyimide Substrate by Bias Sputtering 显示文摘 | Nish M Vanaj K A Sanal K C | 2010 | Materials Science in Semiconductor Processing2010，13，64： | 1 |
| 16 | Clinical features of candidiasis in patients with inherited interleukin 12 receptor β1 deficiency显示文摘 | Ouederni M Sanal O Ikinciogullari A et al | 2014 | Clin Infect Dis2014，58，2： | 1 |
| 17 | Mulations of chronic granulomalous disease in Turkish Families 显示文摘 | Koker MY Sanal O De Boer M | 2007 | Eur J Clin Invest2007，37，7： | 1 |
| 18 | Analyzing businesscompetition by using fuzzy TOPSIS method: an example of Turkishdomestic airline industry显示文摘 | TORLAK G SEVKLI M SANAL M | 2011 | Expert Systems with Applications2011，38，4： | 1 |
| 19 | Therrnoviscoelastic characterization of a corn- posite solid propellant using tubular test显示文摘 | Sanal Kumar V R | 2003 | Journal of Propulsion and Power2003，19，3： | 1 |
| 20 | Bone marrow MRI:techniques and accuracy for detecting breast cancer metastases 显示文摘 | FLIKINGER FW SANAL SM | 1994 | Magn Reson Imaging1994，12，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员